Wednesday broker round-up
12th Dec 2018 12:51
(Sharecast News) - Photo-Me: Kepler Cheuvreux downgrades to hold with a target price of 115p.
Read moreMinor victory for Indivior in Dr Reddy's court battle
12th Dec 2018 07:40
(Sharecast News) - Indivior received some better news from the US courts overnight in its battle with drugmaker Dr Reddy's, which had developed a copycat version of the UK company's best-selling treatment.
Read moreFTSE 250 movers: Indivior recovers while Superdry slides on broker criticism
11th Dec 2018 14:41
(Sharecast News) - London's FTSE 250 was up 1.61% at 17,773.08 in afternoon trade on Tuesday, as Indivior shook off a run of falls to lead the charge.
Read moreFTSE 250 movers: Thomas Cook flies low, Genus holds fast amid selloff
6th Dec 2018 14:44
(Sharecast News) - London's FTSE 250 was down 2.66% at 17,785.79 in afternoon trade on Thursday, as Thomas Cook led the downward charge following news of its demotion from the index.
Read moreIndivior gets shot of pain relief from Canada
23rd Nov 2018 07:14
(Sharecast News) - As it battles a legal headache in the US, Indivior had some good news north of the border on Friday, as where regulators approved its new long-lasting treatment for opioid addiction.
Read moreIndivior 'should emerge' in time, but analysts cautious for now
21st Nov 2018 13:15
(Sharecast News) - Analysts said Indivior will need to take significant action to reduce the cost base and address its debt arrangements after losing a key US court decision.
Read moreIndivior fights to prevent loss of 80% of Suboxone market share
21st Nov 2018 07:22
(Sharecast News) - A day after a US appeals court judge lifted restrictions on a copycat version of its biggest-selling drug, Indivior said it could lose up to 80% of its market share for the anti-opioid addiction treatment.
Read moreIndivior in freefall as it loses court ruling to block generic Suboxone
20th Nov 2018 15:06
(Sharecast News) - Indivior shares were in freefall in afternoon trading on Tuesday as it emerged that the company had lost an appeals court ruling that could allow Dr Reddy's Laboratories to start selling a generic version of its top-selling opioid addiction treatment, Suboxone Film.
Read moreIndivior's schizophrenia treatment gets FDA green light
19th Nov 2018 16:09
(Sharecast News) - Indivior's extended-release injectable treatment for schizophrenia in adults has been approved by US drug regulators.
Read moreIndivior stays on track in third quarter, awaits court decision
1st Nov 2018 11:26
(Sharecast News) - Tighter cost control from Indivior helped offset weaker pricing pressures on its sales of its Suboxone anti-opioid addiction drug in the third quarter.
Read moreIndivior expects benefits from new US legislation
25th Oct 2018 08:07
(Sharecast News) - Indivior said the US government's new healthcare legislation will make treatment for opioid addiction "more immediately accessible" for patients.
Read moreCiti cautious on Indivior until evidence of acceleration to product release
15th Oct 2018 15:57
(Sharecast News) - Pharmaceuticals business Indivior had its target price lowered from 350p to 240p by investment bank Citi due to concern that there is not "sufficient evidence" that the launch of Sublocade is accelerating.
Read moreMonday broker round-up
15th Oct 2018 13:30
(Sharecast News) - Volution: Numis upgrades to add with a target price of 216p.
Read moreThursday broker round-up
11th Oct 2018 13:05
(Sharecast News) - Restaurant Group: HSBC upgrades to buy with a target price of 370p.
Read moreThursday broker round-up
27th Sep 2018 12:14
(Sharecast News) - Thomas Cook Group: UBS upgrades to neutral with a target price of 60p.
Read more